Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
Feb 1, 2022
Grant Date -
Nov 27, 2014
app pub date -
Mar 14, 2014
filing date -
Mar 14, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20 (pegylated ADI derived from M. hominis), but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully